invega trinza Drug Patent Profile
✉ Email this page to a colleague
When do Invega Trinza patents expire, and when can generic versions of Invega Trinza launch?
Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.
This drug has fifty-two patent family members in twenty-six countries.
The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Invega Trinza
A generic version of invega trinza was approved as paliperidone palmitate by TEVA PHARMS USA on July 6th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for invega trinza?
- What are the global sales for invega trinza?
- What is Average Wholesale Price for invega trinza?
Summary for invega trinza
| International Patents: | 52 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 133 |
| Drug Prices: | Drug price information for invega trinza |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for invega trinza |
| What excipients (inactive ingredients) are in invega trinza? | invega trinza excipients list |
| DailyMed Link: | invega trinza at DailyMed |
Pharmacology for invega trinza
| Drug Class | Atypical Antipsychotic |
Paragraph IV (Patent) Challenges for INVEGA TRINZA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 273 mg/0.875 mL and 410 mg/1.315 mL | 207946 | 1 | 2021-07-14 |
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 819 mg/2.625 mL | 207946 | 1 | 2021-04-30 |
| INVEGA TRINZA | Extended-release Injectable Suspension | paliperidone palmitate | 546 mg/1.75 mL | 207946 | 1 | 2020-06-24 |
US Patents and Regulatory Information for invega trinza
invega trinza is protected by two US patents.
Patents protecting invega trinza
Dosing regimen for missed doses for long-acting injectable paliperidone esters
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
Dosing regimen for missed doses for long-acting injectable paliperidone esters
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-001 | May 18, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-004 | May 18, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-002 | May 18, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-003 | May 18, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for invega trinza
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-001 | May 18, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-002 | May 18, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-004 | May 18, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Janssen Pharms | INVEGA TRINZA | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207946-003 | May 18, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for invega trinza
When does loss-of-exclusivity occur for invega trinza?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16244801
Patent: Dosing regimen for missed doses for long-acting injectable paliperidone esters
Estimated Expiration: ⤷ Sign Up
Patent: 20239611
Patent: Dosing regimen for missed doses for long-acting injectable paliperidone esters
Estimated Expiration: ⤷ Sign Up
Patent: 22221405
Patent: Dosing regimen for missed doses for long-acting injectable paliperidone esters
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2017021383
Patent: regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 25908
Patent: PROGRAMME DE DOSAGE DE DOSES OUBLIEES DESTINE AUX ESTERS DE PALIPERIDONE INJECTABLES A ACTION PROLONGEE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Patent: 88401
Patent: PROGRAMME DE DOSAGE DE DOSES OUBLIEES DESTINE AUX ESTERS DE PALIPERIDONE INJECTABLES A ACTION PROLONGEE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0201027
Estimated Expiration: ⤷ Sign Up
Patent: 0240022
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 23203
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 7185
Patent: СПОСОБ ЛЕЧЕНИЯ ПСИХОЗА, ШИЗОФРЕНИИ ИЛИ БИПОЛЯРНОГО РАССТРОЙСТВА (METHOD OF TREATING PSYCHOSIS, SCHIZOPHRENIA OR BIPOLAR DISORDER)
Estimated Expiration: ⤷ Sign Up
Patent: 1792209
Patent: СХЕМА ВВЕДЕНИЯ ПРОПУЩЕННЫХ ДОЗ ИНЪЕКЦИОННЫХ СЛОЖНЫХ ЭФИРОВ ПАЛИПЕРИДОНА ДЛИТЕЛЬНОГО ДЕЙСТВИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 80416
Patent: SCHÉMA DE TRAITEMENT EN CAS DE DOSES OUBLIÉES POUR DES ESTERS DE PALIPÉRIDONE INJECTABLES À ACTION PROLONGÉE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Patent: SCHÉMA DE TRAITEMENT EN CAS DE DOSES OUBLIÉES POUR DES ESTERS DE PALIPÉRIDONE INJECTABLES À ACTION PROLONGÉE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Patent: 49323
Patent: SCHÉMA POSOLOGIQUE POUR DOSES MANQUÉES POUR ESTERS DE PALIPÉRIDONE INJECTABLES À ACTION PROLONGÉE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 49047
Patent: 用於長效可注射的帕利酮酯的遺漏劑量的投藥療程 (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 49485
Estimated Expiration: ⤷ Sign Up
Patent: 65435
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 4669
Patent: משטר מינון עבור מינונים חסרים של פליפרידון אסטרים הניתנים להזרקה עם פעילות ארוכת טווח (Dosing regimen for missed doses for long-acting injectable paliperidone esters)
Estimated Expiration: ⤷ Sign Up
Patent: 9340
Patent: משטר מינון עבור מינונים חסרים של פליפרידון אסטרים הניתנים להזרקה עם פעילות ארוכת טווח (Dosing regimen for missed doses for long-acting injectable paliperidone esters)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 28221
Estimated Expiration: ⤷ Sign Up
Patent: 28503
Estimated Expiration: ⤷ Sign Up
Patent: 22277
Estimated Expiration: ⤷ Sign Up
Patent: 18510894
Patent: 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
Estimated Expiration: ⤷ Sign Up
Patent: 20090498
Patent: 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Patent: 21130680
Patent: 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Moldova, Republic of
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 917
Patent: Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
Estimated Expiration: ⤷ Sign Up
Patent: 511
Patent: SCHÉMA DE TRAITEMENT EN CAS DE DOSES OUBLIÉES POUR DES ESTERS DE PALIPÉRIDONE INJECTABLES À ACTION PROLONGÉE
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5952
Patent: Dosing regimen for missed doses for long-acting injectable paliperidone esters
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 510
Patent: DOZNI REŽIM ZA PROPUŠTENE DOZE INJEKTIBILNIH ESTARA PALIPERIDONA SA PRODUŽENIM DELOVANJEM (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Patent: 024
Patent: DOZNI REŽIM ZA PROPUŠTENE DOZE INJEKTIBILNIH ESTARA PALIPERIDONA SA PRODUŽENIM DELOVANJEM (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 80416
Estimated Expiration: ⤷ Sign Up
Patent: 44326
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2606678
Estimated Expiration: ⤷ Sign Up
Patent: 170134583
Patent: 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
Estimated Expiration: ⤷ Sign Up
Patent: 230162162
Patent: 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 (Dosing regimen for missed doses for long-acting injectable paliperidone esters)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 02299
Estimated Expiration: ⤷ Sign Up
Patent: 67585
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 94825
Estimated Expiration: ⤷ Sign Up
Patent: 1642863
Patent: Dosing regimen for missed doses for long-acting injectable Paliperidone esters
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 8732
Patent: СХЕМА ВВЕДЕННЯ ПРОПУЩЕНИХ ДОЗ ЕСТЕРІВ ПАЛІПЕРИДОНУ ТРИВАЛОЇ ДІЇ ДЛЯ ІН'ЄКЦІЙНОГО ЗАСТОСУВАННЯ (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering invega trinza around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 116583270 | 与延长释放帕潘立酮可注射制剂相关的给药方案 (Dosing regimens associated with extended release paliperidone injectable formulations) | ⤷ Sign Up |
| Germany | 122011100027 | ⤷ Sign Up | |
| Canada | 3203448 | SCHEMAS POSOLOGIQUES ASSOCIES A DES FORMULATIONS INJECTABLES DE PALIPERIDONE A LIBERATION PROLONGEE (DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONS) | ⤷ Sign Up |
| Finland | 4025188 | ⤷ Sign Up | |
| Eurasian Patent Organization | 037185 | СПОСОБ ЛЕЧЕНИЯ ПСИХОЗА, ШИЗОФРЕНИИ ИЛИ БИПОЛЯРНОГО РАССТРОЙСТВА (METHOD OF TREATING PSYCHOSIS, SCHIZOPHRENIA OR BIPOLAR DISORDER) | ⤷ Sign Up |
| European Patent Office | 3280416 | SCHÉMA DE TRAITEMENT EN CAS DE DOSES OUBLIÉES POUR DES ESTERS DE PALIPÉRIDONE INJECTABLES À ACTION PROLONGÉE (DOSING REGIMEN FOR MISSED DOSES FOR LONG-ACTING INJECTABLE PALIPERIDONE ESTERS) | ⤷ Sign Up |
| Israel | 309340 | משטר מינון עבור מינונים חסרים של פליפרידון אסטרים הניתנים להזרקה עם פעילות ארוכת טווח (Dosing regimen for missed doses for long-acting injectable paliperidone esters) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for invega trinza
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0904081 | SPC/GB11/044 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304 |
| 0904081 | C00904081/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PALIPERIDON PALMITATESTER; REGISTRATION NO/DATE: SWISSMEDIC 60466 20101215 |
| 0904081 | 416 | Finland | ⤷ Sign Up | |
| 0904081 | 11C0035 | France | ⤷ Sign Up | PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304 |
| 0368388 | SPC/GB07/065 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 |
| 0904081 | CA 2011 00020 | Denmark | ⤷ Sign Up | |
| 0904081 | PA2011008,C0904081 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONI PALMITAS; REGISTRATION NO/DATE: EU/1/11/672/001 - EU/1/11/672/006 20110304 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
